AbbVie stock nears its record high after a quarterly beat

Published on 09/25/2026 at 12:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AbbVie stock reached USD 265.07 on September 24, 2026, while its quarterly EPS beat consensus by USD 0.04. Revenue rose 10.2 percent year over year to USD 16.99 billion.

Fotorealistisches Pharma-Forschungslabor mit Petrischalen und Wissenschaftlern in Schutzkleidung — AbbVie Inc. US00287Y1091 fotorealistisches Pharma Forschungslabor mit Petrischalen Wissenschaftlern Immunologie Onkologie Biopharma, Illustration mit AI erstellt.

AbbVie stock (ISIN US00287Y1091) stood at USD 265.07 on the NYSE on September 24, 2026, just 1.60 percent below its 52-week high of USD 269.39. The latest quarterly report delivered an EPS beat and revenue growth that help explain the elevated valuation.

Quarterly EPS beats consensus

According to MarketBeat in its September 11, 2026 coverage, AbbVie reported Q2 2026 EPS of USD 3.65, above the USD 3.61 consensus estimate by USD 0.04. The same report put quarterly revenue at USD 16.99 billion against a USD 16.80 billion consensus estimate.

Revenue increased 10.2 percent from the same quarter a year earlier, while prior-year EPS was USD 2.97, according to MarketBeat. The comparison matters because the company is replacing Humira-era revenue with newer growth products while preserving quarterly earnings momentum.

Analyst target stays above price

MarketBeat reported a Moderate Buy consensus and an average analyst target of USD 276.64 on September 11, 2026. That target stands USD 11.57 above the September 24 reference price, a 4.36 percent premium.

In a separate September 10, 2026 report, MarketBeat said HSBC raised its price target from USD 300 to USD 315 and maintained a Buy rating. The gap between the consensus target and HSBC target shows that analyst expectations remain spread even after the recent advance.

Guidance sets the next test

AbbVie set Q3 2026 EPS guidance at USD 3.840-3.880, according to MarketBeat. For investors, the next comparison is therefore between the Q3 result and that guidance range, rather than the already completed Q2 beat.

Stock remains near yearly high

AbbVie traded at USD 265.07 on the NYSE at 7:59 p.m. UTC on September 24, 2026, compared with a prior close of USD 265.08 and a daily change of -0.00 percent. The session range was USD 263.09 to USD 267.41, and volume was 3,429,067 shares.